Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Allergo Journal
Erschienen in: Allergo Journal 8/2018

11.12.2018 | Asthma bronchiale | Leitlinien

EAACI/GA2LEN/EDF/WAO-Leitlinie für die Definition, Klassifikation, Diagnose und das Management der Urtikaria — konsentierte, deutschsprachige Übersetzung

Leitlinie der European Academy of Allergology and Clinical Immunology (EAACI), des Global Allergy and Asthma European Network (GA2LEN), des European Dermatology Forum (EDF) und der World Allergy Organization (WAO)

verfasst von: Prof. Dr. Torsten Zuberbier, Werner Aberer, Riccardo Asero, Amir Hamzah Abdul Latiff, Diane Baker, Barbara Ballmer-Weber, Jonathan A. Bernstein, Carsten Bindslev-Jensen, Zenon Brzoza, Roberta Buense Bedrikow, Giorgio Walter Canonica, Martin K. Church, Timothy Craig, Inna Vladimirovna Danilycheva, Corinna Dressler, Luis Felipe Ensina, Ana Giménez-Arnau, Kiran Godse, Margarida Goncalo, Clive Grattan, Jacques Hebert, Michihiro Hide, Allen Kaplan, Alexander Kapp, Constance H. Katelaris, Emek Kocatürk, Kanokvalai Kulthanan, Désirée Larenas-Linnemann, Tabi A. Leslie, Markus Magerl, Pascale Mathelier-Fusade, Raisa Y. Meshkova, Martin Metz, Alexander Nast, Eustachio Nettis, Hanneke Oude-Elberink, Stefanie Rosumeck, Sarbjit S. Saini, Mario Sánchez-Borges, Peter Schmid-Grendelmeier, Petra Staubach, Gordon Sussman, Elias Toubi, Gino A. Vena, Christian Vestergaard, Bettina Wedi, Ricardo N. Werner, Zuotao Zhao, Marcus Maurer, Randolf Brehler, Knut Brockow, Joachim Fluhr, Jürgen Grabbe, Eckard Hamelmann, Karin Hartmann, Thilo Jakob, Hans Merk, Markus Ollert, Hagen Ott, Imke Reese, Franziska Rueff, Thomas Werfel

Erschienen in: Allergo Journal | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Diese evidenz- und konsensbasierte Leitlinie wurde entsprechend den Methoden der Cochrane und der Grading of Recommendations Assessment, Development and Evaluation (GRADE)-Arbeitsgruppen entwickelt. Die Leitlinien-Konferenz fand am 1. Dezember 2016 statt. Sie ist eine gemeinsame Initiative der European Academy of Allergology and Clinical Immunology (EAACI), dem von der EU gegründeten Global Allergy and Asthma European Network (GA2LEN), dem European Dermatology Forum (EDF) und der World Allergy Organization (WAO) mit 48 teilnehmenden Delegierten aus 42 nationalen und internationalen Gesellschaften.
Die Leitlinie ist von der European Union of Medical Specialists (UEMS) akzeptiert worden. Urtikaria ist eine häufige, mastzellabhängige Erkrankung, die mit Quaddeln, Angioödemen oder beidem einhergeht. Die Lebenszeitprävalenz der akuten Urtikaria liegt bei circa 20 %. Chronische spontane Urtikaria (CSU) und andere chronische Formen der Urtikaria sind belastend, beeinträchtigen die Lebensqualität und haben einen negativen Einfluss auf die Leistungsfähigkeit in Beruf und Schule. Diese Leitlinie umfasst die Definition und Klassifikation der Urtikaria unter Berücksichtigung der jüngsten Fortschritte in der Identifikation von Ursachen, Auslösefaktoren und Pathomechanismen. Darüber hinaus skizziert sie evidenzbasierte, diagnostische und therapeutische Ansätze für die verschiedenen Subtypen der Urtikaria.
Literatur
1.
Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, et al.. EAACI/GA(2)LEN/ EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64:1417–26PubMedCrossRef
2.
Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM et al. EAACI/GA(2)LEN/ EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427–43PubMedCrossRef
3.
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014;69:868–887PubMedCrossRef
4.
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA- 2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2014;69:e1–29PubMedCrossRef
5.
Dressler C, Rosumeck S, Werner RN, Magerl M, Metz M, Maurer M et al. Executive summary: methods and evidence report for the evidence- and consensus-based (S3) Guideline for the definition, classification, diagnosis, and management of urticaria - revision and update 2017. Allergy 2018;73:1145–6PubMedCrossRef
6.
7.
8.
Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011;64:395–400PubMedCrossRef
9.
Finlay AY, Kaplan AP, Beck LA, Antonova EN, Balp MM, Zazzali J, et al. Omalizumab substantially improves dermatology- related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2017;31:1715–21PubMedPubMedCentralCrossRef
10.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490PubMedCrossRef
11.
GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University (developed by Evidence Prime, Inc.); 2015
12.
13.
Haas N, Schadendorf D, Henz BM. Differential endothelial adhesion molecule expression in early and late whealing reactions. Int Arch Allergy Immunol 1998;115:210–4PubMedCrossRef
14.
Peteiro C, Toribio J. Incidence of leukocytoclastic vasculitis in chronic idiopathic urticaria. Study of 100 cases. Am J Dermatopathol 1989;11:528–33PubMedCrossRef
15.
Ito Y, Satoh T, Takayama K, Miyagishi C, Walls AF, Yokozeki H. Basophil recruitment and activation in inflammatory skin diseases. Allergy 2011;66:1107–13PubMedCrossRef
16.
Kay AB, Clark P, Maurer M, Ying S. Elevations in T-helper- 2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (’idiopathic’) urticaria. Br J Dermatol 2015;172:1294–302PubMedCrossRef
17.
Kay AB, Ying S, Ardelean E, Mlynek A, Kita H, Clark P, et al. Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria. Clin Exp Allergy 2014;44:1053–60PubMedCrossRef
18.
Zuberbier T, Schadendorf D, Haas N, Hartmann K, Henz BM. Enhanced P-selectin expression in chronic and dermographic urticaria. Int Arch Allergy Immunol 1997;114:86–9PubMedCrossRef
19.
Kay AB, Ying S, Ardelean E, Mlynek A, Kita H, Clark P, et al. Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with lowlevel persistence in uninvolved skin. Br J Dermatol 2014;171:505–11PubMedPubMedCentralCrossRef
20.
21.
Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002;346:175–9PubMedCrossRef
22.
Hermes B, Prochazka AK, Haas N, Jurgovsky K, Sticherling M, Henz BM. Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 1999;103:307–14PubMedCrossRef
23.
Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011;66:317–30PubMedCrossRef
24.
Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy 2011;66:840–4PubMedCrossRef
25.
Maurer M, Staubach P, Raap U, Richter-Huhn G, Bauer A, Ruëff F, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it’s worse than we thought — first results of the multicenter real-life AWARE study. Clin Exp Allergy 2017;47:684–92PubMedCrossRef
26.
Maurer M, Staubach P, Raap U, Richter-Huhn G, Baier-Ebert M, Chapman-Rothe N. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. Br J Dermatol 2016;174:892–4PubMedCrossRef
27.
Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Giménez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017;72:2005–16PubMedCrossRef
28.
O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197–201PubMedCrossRef
29.
Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003;58:621–3PubMedCrossRef
30.
Parisi CA, Ritchie C, Petriz N, Morelo Torres C. Direct medical costs of chronic urticaria in a private health organization of Buenos Aires, Argentina. Value Health Reg Issues 2016;11:57–9PubMedCrossRef
31.
Broder MS, Raimundo K, Antonova E, Chang E. Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria. Am J Clin Dermatol 2015;16:313–1PubMedPubMedCentralCrossRef
32.
Graham J, McBride D, Stull D, Halliday A, Alexopoulos ST, Balp MM, et al. Cost utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria. Pharmacoeconomics 2016;34:815–27PubMedPubMedCentralCrossRef
33.
Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007;87:196–205PubMed
34.
Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol 2017;139:1772–81PubMedCrossRef
35.
36.
Kolkhir P, Balakirski G, Merk HF, Olisova O, Maurer M. Chronic spontaneous urticaria and internal parasites—a systematic review. Allergy 2016;71:308–22PubMedCrossRef
37.
Imbalzano E, Casciaro M, Quartuccio S, Minciullo PL, Cascio A, Calapai G, et al. Association between urticaria and virus infections: a systematic review. Allergy Asthma Proc 2016;37:18–22PubMedCrossRef
38.
Minciullo PL, Cascio A, Barberi G, Gangemi S. Urticaria and bacterial infections. Allergy Asthma Proc 2014;35:295–302PubMedCrossRef
39.
Foti C, Nettis E, Cassano N, Di Mundo I, Vena GA. Acute allergic reactions to Anisakis simplex after ingestion of anchovies. Acta Derm Venereol 2002;82:121–3PubMedCrossRef
40.
Ventura MT, Napolitano S, Menga R, Cecere R, Asero R. Anisakis simplex hypersensitivity is associated with chronic urticaria in endemic areas. Int Arch Allergy Immunol 2013;160:297–300PubMedCrossRef
41.
Dionigi PC, Menezes MC, Forte WC. A prospective ten-year follow-up of patients with chronic urticaria. Allergol Immunopathol (Madr) 2016;44:286–91CrossRef
42.
Shabrawy RM, Gharib K. Helicobacter pylori Infection as a risk factor in patients suffering from food allergy and urticaria. Egypt J Immunol 2016;23:67–75PubMed
43.
Curth HM, Dinter J, Nigemeier K, Kutting F, Hunzelmann N, Steffen HM. Effects of Helicobacter pylori eradication in chronic spontaneous urticaria: results from a retrospective cohort study. Am J Clin Dermatol 2015;16:553–8PubMedCrossRef
44.
Rasooly MM, Moye NA, Kirshenbaum AS. Helicobacter pylori: a significant and treatable cause of chronic urticaria and angioedema. Nurse Pract 2015;40:1–6PubMedCrossRef
45.
Chen YJ, Wu CY, Shen JL, Chen TT, Chang YT. Cancer risk in patients with chronic urticaria: a population-based cohort study. Arch Dermatol 2012;148:103–8PubMedCrossRef
46.
Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009;64:1256–68PubMedCrossRef
47.
Konstantinou GN, Asero R, Ferrer M, Knol EF, Maurer M, Raap U, et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy 2013;68:27–36PubMedCrossRef
48.
Curto-Barredo L, Yelamos J, Gimeno R, Mojal S, Pujol RM, Gimenez-Arnau A. Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease. Immun Inflamm Dis 2016;4:441–5PubMedPubMedCentralCrossRef
49.
Netchiporouk E, Moreau L, Rahme E, Maurer M, Lejtenyi D, Ben-Shoshan M. Positive CD63 basophil activation tests are common in children with chronic spontaneous urticaria and linked to high disease activity. Int Arch Allergy Immunol 2016;171:81–8PubMedCrossRef
50.
Kim Z, Choi BS, Kim JK, Won DI. Basophil markers for identification and activation in the indirect basophil activation test by flow cytometry for diagnosis of autoimmune urticaria. Ann Lab Med 2016;36:28–35PubMedCrossRef
51.
Iqbal K, Bhargava K, Skov PS, Falkencrone S, Grattan CE. A positive serum basophil histamine release assay is a marker for ciclosporinresponsiveness in patients with chronic spontaneous urticaria. Clin Transl Allergy 2012;2:19PubMedPubMedCentralCrossRef
52.
Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol 2017;139:1059–61PubMedCrossRef
53.
Grattan CEH, Dawn G, Gibbs S, Francis DM. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy 2003;33:337–41PubMedCrossRef
54.
Eckman JA, Hamilton RG, Gober LM, Sterba PM, Saini SS. Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J Invest Dermatol 2008;128:1956–63PubMedCrossRef
55.
Saini SS, Omachi TA, Trzaskoma B, Hulter HN, Rosén K, Sterba PM, et al. Effect of omalizumab on blood basophil counts in patients with chronic idiopathic/spontaneous urticaria. J Invest Dermatol 2017;137:958–61PubMedCrossRef
56.
Kolkhir P, Andre F, Church MK, Maurer M, Metz M. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy 2017;47:19–36PubMedCrossRef
57.
Asero R, Marzano AV, Ferrucci S, Cugno M. D-dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int Arch Allergy Immunol 2017;172:40–4PubMedCrossRef
58.
Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy 2008;63:777–8PubMedCrossRef
59.
Hawro T, Ohanyan T, Schoepke N, Metz M, Peveling-Oberhag A, Staubach P, et al. Comparison and interpretability of the available urticaria activity scores. Allergy 2017;73:251–5PubMedCrossRef
60.
Weller KG, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development, validation and initial results of the angioedema activity score. Allergy 2013;68:1185–92PubMed
61.
Ohanyan T, Schoepke N, Bolukbasi B, Metz M, Hawro T, Zuberbier T, et al. Responsiveness and minimal important difference of the urticaria control test. J Allergy Clin Immunol 2017;140:1710–13PubMedCrossRef
62.
Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014; 133:1365–72PubMedCrossRef
63.
Martinez-Escala ME, Curto-Barredo L, Carnero L, Pujol RM, Gimenez-Arnau AM. Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study. Acta Derm Venereol 2015;95:278–82PubMedCrossRef
64.
Abajian M, Curto-Barredo L, Krause K, Santamaria E, Izquierdo I, Church MK, et al. Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria. Acta Derm Venereol 2016;96:56–9PubMedCrossRef
65.
Mlynek A, Magerl M, Siebenhaar F, Weller K, Vieira Dos Santos R, Zuberbier T, et al. Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Br J Dermatol 2010;162:198–200PubMedCrossRef
66.
Koch K, Weller K, Werner A, Maurer M, Altrichter S. Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. J Allergy Clin Immunol 2016;138:1483–5PubMedCrossRef
67.
Maurer M, Schütz A, Weller K, Schoepke N, Peveling-Oberhag A, Staubach P, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol 2017;140:870–3PubMedCrossRef
68.
Metz M, Schütz A, Weller K, Gorczyza M, Zimmer S, Staubach P, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol 2017;140:864–7PubMedCrossRef
69.
Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias — the EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy 2016;71:780–802PubMedCrossRef
70.
Magerl M, Abajian M, Krause K, Altrichter S, Siebenhaar F, Church MK. An improved Peltier effect-based instrument for critical temperature threshold measurement in coldand heat-induced urticaria. J Eur Acad Dermatol Venereol 2015;29:2043–5PubMedCrossRef
71.
Schoepke N, Abajian M, Church MK, Magerl M. Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism. Clin Exp Dermatol 2015;40:399–403PubMedCrossRef
72.
Mlynek A, Vieira dos Santos R, Ardelean E, Weller K, Magerl M, Church MK, et al. A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clin Exp Dermatol 2013;38:360–6PubMedCrossRef
73.
Altrichter S, Salow J, Ardelean E, Church MK, Werner A, Maurer M. Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. J Dermatol Sci 2014;75:88–93PubMedCrossRef
74.
Azkur D, Civelek E, Toyran M, Msrlolu ED, Erkoolu M, Kaya A, et al. Clinical and etiologic evaluation of the children with chronic urticaria. Allergy Asthma Proc 2016;37:450–7PubMedCrossRef
75.
Lee SJ, Ha EK, Jee HM, Lee KS, Lee SW, Kim MA, et al. Prevalence and risk factors of urticaria with a focus on chronic urticaria in children. Allergy Asthma Immunol Res 2017;9:212–9PubMedPubMedCentralCrossRef
76.
Church MK, Weller K, Stock P, Maurer M. Chronic spontaneous urticaria in children: itching for insight. Pediatr Allergy Immunol 2011;22:1–8PubMedCrossRef
77.
Maurer M, Church MK, Weller K. Chronic urticaria in children — still itching for insight. JAMA Dermatol 2017;153:1221–2PubMedCrossRef
78.
Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, Kone-Paut I, Goldbach-Mansky R, Lachmann H, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis 2017;76:942–7PubMedCrossRef
79.
Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal antiinflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol 2015;136:245–51PubMedCrossRef
80.
Shakouri A, Compalati E, Lang DM, Khan DA. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the grading of recommendations assessment, development, and evaluation system. Curr Opin Allergy Clin Immunol 2010;10:362–9PubMedCrossRef
81.
Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review. Gastroenerol Hepatol Bed Bench 2015;8(Suppl1):6–14.
82.
Henz BM, Zuberbier T. Causes of urticaria. In: Henz BM, Zuberbier T, Grabbe J, Monroe E, eds. Urticaria — clinical, diagnostic and therapeutic aspects. Berlin: Springer; 1998
83.
Ergon MC, Ilknur T, Yucesoy M, Ozkan S. Candida spp. Colonization and serum anticandidal antibody levels in patients with chronic urticaria. Clin Exp Dermatol 2007;32:740–3PubMedCrossRef
84.
Zuberbier T, Chantraine-Hess S, Hartmann K, Czarnetzki BM. Pseudoallergen-free diet in the treatment of chronic urticaria — a prospective study. Acta Derm Venereol 1995;75:484–7PubMed
85.
Bruno G, Andreozzi P, Graf U. Exercise-induced urticariaangioedema syndrome: a role in gastroesophageal reflux. In: Vena GA, Puddu P, eds. Proceedings of the international symposium on urticaria. Bari, Milan: Editrice CSH; 1998: 85–9
86.
Varghese R, Rajappa M, Chandrashekar L, Kattimani S, Archana M, Munisamy M, et al. Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticaria. Ann Allergy Asthma Immunol 2016;116:344–8PubMedCrossRef
87.
Kounis NG, Kounis GN, Soufras GD. Exercise-induced urticaria, cholinergic urticaria, and Kounis syndrome. J Pharmacol Pharmacother 2016;7:48–50PubMedPubMedCentralCrossRef
88.
Grattan CE, Francis DM, Slater NG, Barlow RJ, Greaves MW. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 1992;339:1078–80PubMedCrossRef
89.
Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol 1981;104:369–81PubMedCrossRef
90.
Pfrommer C, Bastl R, Vieths S, Ehlers I, Henz BM, Zuberbier T. Characterization of naturally occurring pseudoallergens causing chronic urticaria. J Allergy Clin Immunol 1996;97:367CrossRef
91.
92.
Bunselmeyer B, Laubach HJ, Schiller M, Stanke M, Luger TA, Brehler R. Incremental build-up food challenge — a new diagnostic approach to evaluate pseudoallergic reactions in chronic urticaria: a pilot study: stepwise food challenge in chronic urticaria. Clin Exp Allergy 2009;39:116–26PubMedCrossRef
93.
Nettis E, Colanardi MC, Ferrannini A, Tursi A. Sodium benzoateinduced repeated episodes of acute urticaria/angio- oedema: randomized controlled trial. Br J Dermatol 2004;151:898–902PubMedCrossRef
94.
Akoglu G, Atakan N, Cakir B, Kalayci O, Hayran M. Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria. Arch Dermatol Res 2012;304:257–62PubMedCrossRef
95.
Wagner N, Dirk D, Peveling-Oberhag A, Reese I, Rady-Pizarro U, Mitzel H, et al. A Popular myth — low-histamine diet improves chronic spontaneous urticaria — fact or fiction? J Eur Acad Dermatol Venereol 2016;31:650–5PubMedCrossRef
96.
Beissert S, Stander H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol 2000;42:1030–2PubMedCrossRef
97.
Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009;64:605–12PubMedCrossRef
98.
Weller K, Ardelean E, Scholz E, Martus P, Zuberbier T, Maurer M. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, Single-dose study. Acta Derm Venereol 2013;93:168–74PubMedCrossRef
99.
100.
Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H (1)-antihistamines: a GA(2)LEN position paper. Allergy 2010;65:459–66PubMedCrossRef
101.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and ist Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8–160PubMedCrossRef
102.
Kubo N, Senda M, Ohsumi Y, Sakamoto S, Matsumoto K, Tashiro M, et al. Brain histamine H1 receptor occupancy of loratadine measured by positron emission topography: comparison of H1 receptor occupancy and proportional impairment ratio. Hum Psychopharmacol 2011;26:133–9PubMedCrossRef
103.
Kontou-Fili K, Paleologos G, Herakleous M. Suppression of histamine-induced skin reactions by loratadine and cetirizine diHCl. Eur J Clin Pharmacol 1989;36:617–9PubMedCrossRef
104.
Zuberbier T, Munzberger C, Haustein U, Trippas E, Burtin B, Mariz SD, et al. Double-blind crossover study of highdose cetirizine in cholinergic urticaria. Dermatology 1996;193:324–7PubMedCrossRef
105.
Kontou-Fili KK, Maniakatou G, Demaka P. Therapeutic effect of cetirizine 2 HCl in delayed pressure urticaria. Health Sci Rev 1989;3:23–5
106.
Wanderer AA, Ellis EF. Treatment of cold urticaria with cyproheptadine. J Allergy Clin Immunol 1971;48:366–71PubMedCrossRef
107.
Kaplan AP, Gray L, Shaff RE, Horakova Z, Beaven MA. In vivo studies of mediator release in cold urticaria and cholinergic urticaria. J Allergy Clin Immunol 1975;55:394–402PubMedCrossRef
108.
Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult- to-treat urticaria. J Allergy Clin Immunol 2010;125:676–82PubMedCrossRef
109.
Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. Highdose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard—dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009;123:672–9PubMedCrossRef
110.
Gimenez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo—controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol 2009;23:1088–91PubMedCrossRef
111.
Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, Guillen-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and metaanalysis. Br J Dermatol 2016;175:1153–65PubMedCrossRef
112.
Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine- refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567–73.e1PubMedCrossRef
113.
Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128:202–9PubMedCrossRef
114.
Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015;135:67–75PubMedCrossRef
115.
Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924–35PubMedCrossRef
116.
Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101–9PubMedCrossRef
117.
Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016;137:1742–50PubMedCrossRef
118.
Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol 2018; 141:638–49PubMedCrossRef
119.
Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011;154:177–80PubMedCrossRef
120.
Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008;63:247–9PubMedCrossRef
121.
Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006;117:1415–8PubMedCrossRef
122.
Guzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M. Successful treatment of solar urticaria with antiimmunoglobulin E therapy. Allergy 2008;63:1563–5PubMedCrossRef
123.
Bullerkotte U, Wieczorek D, Kapp A, Wedi B. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy 2010;65:931–2PubMedCrossRef
124.
Krause K, Ardelean E, Kessler B, Magerl M, Metz M, Siebenhaar F, et al. Antihistamine-resistant urticarial factitia successfully treated with anti-immunoglobulin E therapy. Allergy 2010;65:1494–5PubMedCrossRef
125.
Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 2010;65:138–9PubMedCrossRef
126.
Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Canvin J et al. Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 2016;71:1135–44PubMedCrossRef
127.
Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/ spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol 2017;31:1056–63PubMedPubMedCentralCrossRef
128.
Maurer M, Kaplan A, Rosén K, Holden M, Iqbal A, Trzaskoma BL, et al. The XTEND-CIU study: Long term use of Omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol 2018;141:1138–9.e7PubMedCrossRef
129.
Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014;150:288–90PubMedCrossRef
130.
Stellato C, de Paulis A, Ciccarelli A, Cirillo R, Patella V, Casolaro V, et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992;98:800–4PubMedCrossRef
131.
Harrison CA, Bastan R, Peirce MJ, Munday MR, Peachell PT. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol 2007;150:509–18PubMedPubMedCentralCrossRef
132.
Grattan CE, O’Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, et al. Randomized doubleb-lind study of cyclosporin in chronic ’idiopathic’ urticaria. Br J Dermatol 2000;143:365–72PubMedCrossRef
133.
Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006;55:705–9PubMedCrossRef
134.
Kulthanan K, Chaweekulrat P, Komoltri C, Hunnangkul S, Tuchinda P, Chularojanamontri L, et al. Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. J Allergy Clin Immunol Pract 2018;6:586–99PubMedCrossRef
135.
Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol 2009;26:409–13PubMedCrossRef
136.
Zuberbier T, Ifflander J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol 1996;76:295–7PubMed
137.
Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol 2010;20:386–90PubMed
138.
Rutkowski K, Grattan CEH. How to manage chronic urticaria ’beyond’ guidelines: a practical algorithm. Clin Exp Allergy 2017;47:710–8PubMedCrossRef
139.
Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol 2007;119:752–4PubMedCrossRef
140.
O’Donnell BF, Barr RM, Black AK, Francis DM, Kermani F, Niimi N, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998;138:101–6PubMedCrossRef
141.
Dawn G, Urcelay M, Ah-Weng A, O’Neill SM, Douglas WS. Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria. Br J Dermatol 2003;149: 836–40PubMedCrossRef
142.
Pereira C, Tavares B, Carrapatoso I, Loureiro G, Faria E, Machado D, et al. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Eur Ann Allergy Clin Immunol 2007;39:237–42PubMed
143.
Mitzel-Kaoukhov H, Staubach P, Muller-Brenne T. Effect of highdose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria. Ann Allergy Asthma Immunol 2010;104:253–8PubMedCrossRef
144.
Bangsgaard N, Skov L, Zachariae C. Treatment of refractory chronic spontaneous urticaria with adalimumab. Acta Derm Venereol 2017;97:524–5PubMedCrossRef
145.
Sand FL, Thomsen SF. TNF-alpha inhibitors for chronic urticaria: experience in 20 patients. J Allergy (Cairo) 2013;2013:130905
146.
Hannuksela M, Kokkonen EL. Ultraviolet light therapy in chronic urticaria. Acta Derm Venereol 1985;65:449–50PubMed
147.
Borzova E, Rutherford A, Konstantinou GN, Leslie KS, Grattan CEH. Narrow-band ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study. J Am Acad Dermatol 2008;59:752–7PubMedCrossRef
148.
Engin B, Ozdemir M, Balevi A, Mevlitoglu I. Treatment of chronic urticaria with narrow-band ultraviolet B phototherapy: a randomized controlled trial. Acta Derm Venereol 2008;88:247–51PubMed
149.
Thormann J, Laurberg G, Zachariae H. Oral sodium cromoglycate in chronic urticaria. Allergy 1980;35:139–41PubMedCrossRef
150.
Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. Acta Derm Venereol 1977;57:369–70PubMed
151.
Lawlor F, Ormerod AD, Greaves MW. Calcium antagonist in the treatment of symptomatic dermographism. Lowdose and high-dose studies with nifedipine. Dermatologica 1988;177:287–91PubMedCrossRef
152.
Lawlor F, Black AK, Ward AM, Morris R, Greaves MW. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol 1989;120:403–8PubMedCrossRef
153.
Dover JS, Black AK, Ward AM, Greaves MW. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. J Am Acad Dermatol 1988;18:1289–98PubMedCrossRef
154.
Asero R, Tedeschi A, Cugno M. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol 2010;152:384–9PubMedCrossRef
155.
Nayak AS, Berger WE, LaForce CF, Urdaneta ER, Patel MK, Franklin KB, et al. Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. Allergy Asthma Proc 2017;38:222–30PubMedCrossRef
156.
Gupta S, Khalilieh S, Kantesaria B, Banfield C. Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br J Clin Pharmacol 2007;63:534–40PubMedCrossRef
157.
Gupta SK, Kantesaria B, Banfield C, Wang Z. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. Br J Clin Pharmacol 2007;64:174–84PubMedPubMedCentralCrossRef
158.
Meltzer EO, Scheinmann P, Rosado Pinto JE, Bachert C, Hedlin G, Wahn U, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis — a pooled analysis of three studies. Pediatr Allergy Immunol 2004;15:253–60PubMedCrossRef
159.
Pampura AN, Papadopoulos NG, Spicak V, Kurzawa R. Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease. Int Arch Allergy Immunol 2011;155:367–78PubMedCrossRef
160.
Potter P, Mitha E, Barkai L, Mezei GA, Santamaría ES, Izquierdo I, et al. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. Pediatr Allergy Immunol 2016;27:55–61PubMedCrossRef
161.
Novak Z, Yanez A, Kiss I, Kuna P, Tortajada-Girbés M, Valiente R, et al. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatr Allergy Immunol 2016;27:493–8PubMedCrossRef
162.
Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol 2008;26:19–23PubMedCrossRef
163.
Schwarz EBMM, Nayak S, Koren G. Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis. Drug Saf 2008;31:775–88PubMedCrossRef
164.
Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H, Carrigan G, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol 2015;135:407–12PubMedCrossRef
165.
González-Medina M, Curto-Barredo L, Labrador-Horrillo M, Giménez-Arnau A. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases. J Eur Acad Dermatol Venereol 2017;31:e245–e246PubMedCrossRef
166.
Ghazanfar MN, Thomsen SF. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies. Case Rep Med 2015;2015:368053PubMedPubMedCentralCrossRef
167.
Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–6PubMedCrossRef
168.
Maurer M. Cold urticaria. In: Saini SS, Callen J, editors. Up-To-Date. Boston, MA: Wolters Kluwer Health; 2014
Metadaten
Titel
EAACI/GA2LEN/EDF/WAO-Leitlinie für die Definition, Klassifikation, Diagnose und das Management der Urtikaria — konsentierte, deutschsprachige Übersetzung
Leitlinie der European Academy of Allergology and Clinical Immunology (EAACI), des Global Allergy and Asthma European Network (GA2LEN), des European Dermatology Forum (EDF) und der World Allergy Organization (WAO)
verfasst von
Prof. Dr. Torsten Zuberbier
Werner Aberer
Riccardo Asero
Amir Hamzah Abdul Latiff
Diane Baker
Barbara Ballmer-Weber
Jonathan A. Bernstein
Carsten Bindslev-Jensen
Zenon Brzoza
Roberta Buense Bedrikow
Giorgio Walter Canonica
Martin K. Church
Timothy Craig
Inna Vladimirovna Danilycheva
Corinna Dressler
Luis Felipe Ensina
Ana Giménez-Arnau
Kiran Godse
Margarida Goncalo
Clive Grattan
Jacques Hebert
Michihiro Hide
Allen Kaplan
Alexander Kapp
Constance H. Katelaris
Emek Kocatürk
Kanokvalai Kulthanan
Désirée Larenas-Linnemann
Tabi A. Leslie
Markus Magerl
Pascale Mathelier-Fusade
Raisa Y. Meshkova
Martin Metz
Alexander Nast
Eustachio Nettis
Hanneke Oude-Elberink
Stefanie Rosumeck
Sarbjit S. Saini
Mario Sánchez-Borges
Peter Schmid-Grendelmeier
Petra Staubach
Gordon Sussman
Elias Toubi
Gino A. Vena
Christian Vestergaard
Bettina Wedi
Ricardo N. Werner
Zuotao Zhao
Marcus Maurer
Randolf Brehler
Knut Brockow
Joachim Fluhr
Jürgen Grabbe
Eckard Hamelmann
Karin Hartmann
Thilo Jakob
Hans Merk
Markus Ollert
Hagen Ott
Imke Reese
Franziska Rueff
Thomas Werfel
Publikationsdatum
11.12.2018
Verlag
Springer Medizin
Erschienen in
Allergo Journal / Ausgabe 8/2018
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI
https://doi.org/10.1007/s15007-018-1751-3

Weitere Artikel der Ausgabe 8/2018

Allergo Journal 8/2018 Zur Ausgabe

Pharmaforum

DBPC-Studie zu Hausstaubmilbentablette gestartet

Im Fokus

Pflanzenallergene

Pharmaforum

Chronische spontane Urtikaria: AWARE-Studie bestätigt großen Einfluss auf die Lebensqualität

Übersicht

Novel vaccines targeting dendritic cells by coupling allergoids to mannan

Panorama

Permanentmarker löst Kontaktallergie aus

Pharmaforum

CHMP empfiehlt Zulassung von Lanadelumab zur Prophylaxe von HAE-Attacken

Aktuelle Kurse aus dieser Zeitschrift

Orchestrierung der Entzündung bei Kontaktallergie durch angeborene Immun- und zelluläre Stressantworten

Allergien und Intoleranzreaktionen CME-Kurs
CME: 2 Punkte

Entzündung ist von zentraler Bedeutung für die Initiation von Immunantworten und für die Pathogenese zahlreicher Erkrankungen wie der allergischen Kontaktdermatitis („allergic contact dermatitis“, ACD). Der CME-Kurs gibt einen Überblick über das Zusammenspiel von angeborenem Immunsystem und zellulären Stressantworten und Sie lernen, welche Entzündungsmechanismen an der allergischen Kontaktdermatitis beteiligt sind.

Eosinophile Ösophagitis - von der Definition bis zur Therapie

Eosinophile Ösophagitis CME-Kurs
CME: 2 Punkte

Die eosinophile Ösophagitis (EoE) ist eine chronische, progressive, immunvermittelte Erkrankung, die klinisch durch Symptome einer ösophagealen Dysfunktion und histologisch durch eine eosinophile Entzündung der Speiseröhre gekennzeichnet ist. Dieser CME-Artikel gibt einen Überblick über den aktuellen Wissensstand auf dem Gebiet der EoE. 

Akute Urtikaria - was tun?

Urtikaria CME-Kurs
CME: 2 Punkte

Die akute Urtikaria (AU) ist die häufigste Ursache einer Quaddelbildung. Definitionsgemäß besteht sie nicht länger als sechs Wochen. Sie kann in jedem Lebensalter auftreten und wird häufiger bei atopischer Diathese gesehen. Die akute spontane Urtikaria wird von den induzierbaren Formen unterschieden. In dieser CME-Übersichtsarbeit werden Klinik, Differenzialdiagnose, mögliche Auslöser und therapeutische Strategien aufgezeigt. Im Kindesalter wie im Erwachsenenalter sind virale Infekte sehr häufig mit einer akuten Urtikaria assoziiert, während Medikamente und Nahrungsmittel seltener als Auslöser beschrieben werden. Oftmals sind jedoch auch mehrere Trigger gleichzeitig vorhanden. Therapeutisch kommen vor allem orale nicht sedierende H1-Antihistaminika zum Einsatz. Bei einigen Betroffenen wird auch eine begleitende, kurzfristige Gabe von Glukokortikosteroiden nötig.

Das Handbuch für molekulare Allergologie 2.0: Update zu relevanten neuen Inhalten

Allergien und Intoleranzreaktionen CME-Kurs
CME: 4 Punkte

Der erste Leitfaden zur molekularen Allergologie wurde 2016 veröffentlicht und wurde schnell zu einer wichtigen Referenz für viele Kliniker und Wissenschaftler weltweit. Die rasante Entwicklung unseres Wissens über Allergenmoleküle sowie die Verfügbarkeit neuer Assays und neuer klinischer Studien machten eine Aktualisierung des Leitfadens erforderlich. In einer konzertierten Aktion von fast 100 Autoren wurden alle Kapitel der ersten Auflage überarbeitet und neue Kapitel hinzugefügt, wodurch der aktuellste, frei verfügbare Leitfaden zur molekularen Allergologie für die tägliche Praxis entstand. Die CME-Fortbildung gibt einen Überblick über die wichtigsten Neuerungen des Molecular Allergology User’s Guide 2.0, MAUG 2.0 (Ausgabe 2022).